Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,098,322 papers from all fields of science
Search
Sign In
Create Free Account
namitecan
Known as:
(4S)-11-((E)-((2-Aminoethoxy)imino)methyl)-4-ethyl-4-hydroxy-1,12-dihydro-14H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H)-dione
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Broader (2)
Antineoplastic Agents, Phytogenic
Camptothecin
Narrower (1)
ST 1968
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).
M. Joerger
,
D. Hess
,
+7 authors
C. Sessa
British Journal of Clinical Pharmacology
2015
Corpus ID: 207060295
AIMS Namitecan is a new camptothecan compound undergoing early clinical development. This study was initiated to build an…
Expand
2015
2015
Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors
Markus Joerger
,
D. Hess
,
+4 authors
Cristiana Sessa
Investigational new drugs
2015
Corpus ID: 8578429
SummaryPurpose: This is a first-in-human, phase I, dose-escalation study to determine the maximum tolerated dose (MTD) of…
Expand
Review
2014
Review
2014
Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120
U. Geisthoff
,
Ha-Long Nguyen
,
D. Hess
Annals of Hematology
2014
Corpus ID: 20981195
Dear Editor, Hereditary hemorrhagic telangiectasia (HHT, Rendu–Osler– Weber syndrome) is an inherited vascular dysplasia. Typical…
Expand
2014
2014
Cancer Therapy : Preclinical SynergisticAntitumorActivityofCetuximabandNamitecan in Human Squamous Cell Carcinoma Models Relies on Cooperative Inhibition of EGFR Expression and Depends on High EGFR…
M. Cesare
,
C. Lauricella
,
+5 authors
V. Zuco
2014
Corpus ID: 31119564
Purpose:Despite the frequent overexpression of epidermal growth factor receptor (EGFR) in squamous cell carcinoma (SCC), the…
Expand
Review
2012
Review
2012
Namitecan: a hydrophilic camptothecin with a promising preclinical profile.
G. Beretta
,
V. Zuco
,
M. de Cesare
,
P. Perego
,
N. Zaffaroni
Current Medicinal Chemistry
2012
Corpus ID: 46339453
Camptothecins are still among the most widely prescribed and effective anticancer drugs. Unfortunately, important drawbacks…
Expand
2012
2012
Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models
D. Meco
,
A. D. Di Francesco
,
+6 authors
R. Riccardi
Cancer Chemotherapy and Pharmacology
2012
Corpus ID: 7677526
PurposeThe present study aimed to evaluate the new water soluble camptothecin analogue Namitecan (ST1968) in preclinical…
Expand
2011
2011
Phase I clinical trial of namitecan (ST1968): Results with D1-3 q3wks schedule.
A. Fasolo
,
G. Del Conte
,
+11 authors
L. Gianni
Journal of Clinical Oncology
2011
Corpus ID: 43450820
e13570 Background: Namitecan (N) is a topoisomerase I inhibitor with superior antitumor activity (especially in squamous cell ca…
Expand
2009
2009
Clinical development of namitecan (ST1968), a novel camptothecin derivative with high antitumor activity: Phase I clinical data.
D. Hess
,
S. Boehm
,
+7 authors
C. Sessa
Journal of Clinical Oncology
2009
Corpus ID: 29935751
2570 Background: Namitecan is a new water-soluble camptothecin analogue which showed high antitumor activity in preclinical…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE